Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €113.58 EUR
Change Today +2.46 / 2.22%
Volume 48.0
WAZ On Other Exchanges
New York
As of 11:10 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

waters corp (WAZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €119.31
52 Week Low
04/30/14 - €71.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WATERS CORP (WAZ)

waters corp (WAZ) Related Businessweek News

View More BusinessWeek News

waters corp (WAZ) Details

Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. The company's Waters division designs, manufactures, sells, and services high performance liquid chromatography, ultra performance liquid chromatography, and mass spectrometry technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. This segment’s products are used to detect, identify, monitor, and measure the chemical, physical, and biological composition of materials, as well as to purify a range of compounds. Its products are also used in drug discovery and development, including clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its TA division offers thermal analysis, rheometry, and calorimetry instruments, which are used in predicting the suitability of fine chemicals, pharmaceuticals, water, polymers, and viscous liquids for uses in various industrial, consumer goods, and healthcare products, as well as for life science research. The company also develops and supplies software-based products that interface with its instruments. Its products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is based in Milford, Massachusetts.

6,200 Employees
Last Reported Date: 02/27/15
Founded in 1958

waters corp (WAZ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $797.3K
Interim Chief Financial Officer and Vice Pres...
Total Annual Compensation: $340.1K
Executive Vice President and President of the...
Total Annual Compensation: $508.0K
Vice President, General Counsel and Secretary
Total Annual Compensation: $400.7K
Vice President of Human Resources and Vice Pr...
Total Annual Compensation: $245.1K
Compensation as of Fiscal Year 2014.

waters corp (WAZ) Key Developments

Waters Corporation Enters into Amendment to the Credit Agreement

Waters Corporation has entered into an amendment, the first amendment dated as of April 23, 2015, to the credit agreement dated as of June 25, 2013, among the company, the lenders from time to time party hereto; JPMorgan Chase Bank, N.A., as administrative agent and J.P. Morgan Europe Limited, as London agent. Under the terms of the amendment, the parties have agreed principally (i) to increase the revolving commitments from $1.1 billion to $1.3 billion, (ii) to extend the maturity of the loans and other obligations under the credit agreement from June 25, 2018 until April 23, 2020, (iii) to provide for certain changes in the interest rate margins and fees under the credit agreement, as follows: (x) for Alternate Base Rate loans, the interest rate margin based upon company’s leverage ratio was amended to range between 0 basis points and 17.5 basis points, as compared to the previous range of between 0 basis points and 12.5 basis points, (y) for adjusted LIBO Rate or LIBO Rate borrowings, the interest rate margin based upon company's leverage ratio, was amended to range between 80 basis points and 117.5 basis points, as compared to the previous range which was between 75 basis points and 112.5 basis points and (z) the facility fee based upon company's leverage ratio, was amended to range between 7.5 basis points and 20 basis points, as compared to the previous range which was between 12.5 basis points and 25 basis points, and (iv) to amend certain other provisions of the credit agreement to reflect current market practices. Except as modified by the amendment, all of the representations and warranties, affirmative and negative covenants, events of default and other terms of the credit agreement, as in effect prior to the amendment, remain in effect. As of April 23, 2015, the total amount outstanding under the credit agreement prior to the amendment equaled approximately $1,012 million, of which $300 million was outstanding under the term loan facility, $710 million was outstanding under the revolving credit facility, and $2 million was outstanding under the letter of credit facility. These amounts remain outstanding under the credit agreement and the company plans to use the future borrowings for general corporate purposes as provided for under the credit agreement.

Chinese Food and Drug Administration Approves Waters Corporation's ACQUITY UPLC I- Class IVD/Xevo TQ-S IVD System for in Vitro Diagnostic Use in China

Waters Corporation announced that the Chinese Food and Drug Administration (CFDA) approved the Waters ACQUITY UPLC I- Class IVD/Xevo TQ-S IVD System for in vitro diagnostic (IVD) use in China. The system was approved for clinical analysis of a variety of compounds that include diagnostic indicators and compounds for treatment monitoring. To facilitate this transition, better diagnostic and predictive tools are needed so that disease can be detected earlier or even prevented. That is where Waters technologies like the ACQUITY TQD System and ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD systems, approved for IVD use by the CFDA in 2014 and 2015, respectively, can make a significant impact. Using LC-MS technology, clinical laboratories perform qualitative and quantitative analyses of patients' samples to aid clinicians in many ways. These tests may be used to confirm a clinical suspicion (including making a diagnosis); assist in the selection, optimization and monitoring of treatment; provide a prognosis; screen for disease in the absence of clinical signs or symptoms; and establish and monitor the severity of physiological disturbance. Liquid chromatography separates analytes and interferents within a given sample, while mass spectrometry technology is used for detection and confirmation of those analytes. The recently CFDA approved ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD System features Waters' Ultra Performance LC technology coupled with a tandem quadrupole mass spectrometer designed for the most demanding UPLC-MS/MS quantitative analysis. This system uses StepWave, a breakthrough off-axis ion source technology, and RADAR, an information rich acquisition method, enabling the system with sensitivity and robustness.

Waters Corporation expected to report Q1 2015 results on April 27, 2015. This event was calculated by Capital IQ (Created on April 8, 2015).

Waters Corporation expected to report Q1 2015 results on April 27, 2015. This event was calculated by Capital IQ (Created on April 8, 2015).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WAZ:GR €113.58 EUR +2.46

WAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bruker Corp $19.22 USD +0.23
Cintas Corp $81.50 USD -0.12
Mettler-Toledo International Inc $322.81 USD +2.79
PerkinElmer Inc $51.60 USD +0.06
WR Grace & Co $97.31 USD +0.115
View Industry Companies

Industry Analysis


Industry Average

Valuation WAZ Industry Range
Price/Earnings 24.4x
Price/Sales 5.2x
Price/Book 5.4x
Price/Cash Flow 23.1x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WATERS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at